TNGXHealthcare · BiotechnologyThe 13 Wall Street analysts covering Tango Therapeutics, Inc. hold a median 12-month price target of $46 — +97.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 24 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Tango Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (92): The shares have been drifting up relative to others.
Accruals (23): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TNGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +97.2% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Oct 2026 | William Blair | Initiates | Outperform | — |
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $66 → $68 |
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Aug 2026 | Guggenheim | Maintains | Buy | $32 → $35 |
| 12 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 17 July 2026 | Mizuho | Maintains | Outperform | $36 → $40 |
| 17 July 2026 | Mizuho | Maintains | Outperform | — |
| 15 July 2026 | JP Morgan | Initiates | Overweight | $46 |
| 15 July 2026 | JP Morgan | Initiates | Overweight | — |
| 29 June 2026 | Canaccord Genuity | Maintains | Buy | $42 → $46 |
| 29 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 26 June 2026 | Jefferies | Upgrade | Buy | $27 → $60 |
| 26 June 2026 | Jefferies | Upgrade | Buy | — |
| 11 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 15 May 2026 | Mizuho | Maintains | Outperform | — |
| 15 May 2026 | Piper Sandler | Downgrade | Neutral | — |
| 14 May 2026 | Jefferies | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TNGX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Tango Therapeutics, Inc. returned +209.8% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 4% of US stocks
Cheaper than 24% of US stocks
Cheaper than 90% of US stocks
Higher than 1% of US stocks
Higher than 10% of US stocks
Higher than 2% of US stocks
Higher than 31% of US stocks
Higher than 24% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tango Therapeutics, Inc. has a market value of $3.9B and an enterprise value of $3.0B.
Revenue in the twelve months to 30 June 2026: $53.8M.
Net income over the same four quarters: −$123.7M, a −229.9% net margin.
Diluted earnings per share, trailing twelve months: $−0.85.
Free cash flow in the twelve months to 30 June 2026: −$144.3M.
Trailing P/E: −26.8×; forward P/E: −14.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Tango Therapeutics, Inc. employs 137 people — $393K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Tango Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript discussing updated vopimetastat combination data and Tango Therapeutics’ registration strategy in pancreatic cancer.
Why it matters — The transcript concerns clinical data and the potential registration path for a TNGX program in pancreatic cancer.
Tango Therapeutics said it plans to start a global Phase III trial in the first half of 2027. The study will evaluate vopimetostat with daraxonrasib as first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma.
Why it matters — The planned trial is a development milestone for TNGX’s combination therapy in this patient population.
Tango Therapeutics shared Phase 1/2 trial data for investigational vopimetostat, reporting strong efficacy in advanced pancreatic and lung cancers.
Why it matters — The trial results provide TNGX watchers an update on the drug’s early clinical performance in two advanced cancers.
Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines’ newly approved drug in pancreatic cancer.
Why it matters — The update concerns a TNGX combination in pancreatic cancer and reports results above expectations.
Tango reported Phase 1/2 results for vopimetostat plus daraxonrasib in patients with second- or third-line pancreatic cancer: an 82% objective response rate, median progression-free survival not yet reached, and a 9-month progression-free survival rate of 88%.
Why it matters — The reported combination-trial results and development-strategy update are relevant to TNGX watchers tracking the company’s pancreatic cancer programs.
The 13 Wall Street analysts covering Tango Therapeutics, Inc. have a median 12-month price target of $46, with estimates ranging from $24 to $69. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Tango Therapeutics, Inc., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tango Therapeutics, Inc. 42 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Tango Therapeutics, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +97.2% from the last close, and Ticker Nerd's factor model ranks Tango Therapeutics, Inc. 42 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Tango Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $69 over the next 12 months.
Tango Therapeutics, Inc. returned +209.8% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision cancer medicines for patients with significant unmet medical needs.
The most recent item we track (Seeking Alpha, 23 Oct 2026): "Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript". Seeking Alpha published a transcript discussing updated vopimetastat combination data and Tango Therapeutics’ registration strategy in pancreatic cancer.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision cancer medicines for patients with significant unmet medical needs. The company applies synthetic lethality research to identify drug targets linked to specific genetic vulnerabilities in cancer cells, with an emphasis on tumor suppressor gene loss. Its current pipeline centers on precision oncology programs, including PRMT5 inhibitors and related targeted therapies designed for defined patient populations. Tango Therapeutics is developing treatments for hard-to-treat cancers such as pancreatic cancer, lung cancer, glioblastoma, and other genetically defined solid tumors. The company’s research and development activities position it within the oncology drug discovery segment, where targeted therapies play an important role in advancing more selective approaches to cancer treatment. Based in Boston, Massachusetts, Tango Therapeutics operates as a specialized biopharmaceutical company dedicated to translating genetic insights into new cancer medicines.
CEO Dr. Malte Peters M.D. · 137 employees · United States · https://www.tangotx.com
